Johnson & Johnson topped IDEA Pharma's third annual Productive Innovation Index, which seeks to rank drugmakers by their ability to launch innovative products. J&J's rank can be attributed to the commercialization of prostate cancer treatment Zytiga, or abiraterone, IDEA CEO Mike Rea said. Amgen, last year's No. 1, was second, followed by Roche. Rounding out the top 10 were Merck & Co., Sanofi, Eli Lilly & Co., Novartis, GlaxoSmithKline, Bristol-Myers Squibb and Abbott.
J&J leads ranking of most productive pharmaceutical firms
SmartBrief Job Listings for Health Care
|Manager of Payer Relations||
Pharmacy Quality Solutions, Inc.
|President/Chief Executive Officer||
|Consumer Directed Health Plan (CDH) Product Offering Manager||
Blue Cross Blue Shield MA
|Director, Payer Marketing||
Meridian Health Plan